Lung Metastasis from Perineal Leiomyosarcoma: A Case Report and a Review of the Japanese Literature

Table 2

Lung metastases from a leiomyosarcoma treated by chemotherapy alone over the last 10 years in Japan (2001–2011).

	Sex	Age	Primary lesion	Chemotherapy	Prognosis (after diagnosis of the lung metastasis)	Reference
1	Male	77	Mesocolon transversum	Doxorubicin + ifosfamide	Unknown	[8]
2^†	Female	39	Uterus	CyVADIC-etoposide	One year and one month	[9]
3^†	Female	41	Urinary bladder	Dacarbazine + adriamycin + vincristine + cyclophosphamide	One year and three months	[10]
4^†	Female	55	Uterus	Cisplatin + docetaxel→irinotecan	Two years and three months	[11]
5	Female	48	Uterus	IA→CPT-11→docetaxel + gemcitabine	Eight months	[12]
6	Female	48	Uterus	CAP→IAP	Two years and five months	[13]
7	Female	68	Retroperitoneum	CyVADIC→MAID	Ten months	[14]
8^†	Female	71	Uterus	Docetaxel + gemcitabine	Two months	[15]
9	Female	49	Uterus	HEEp-DTIC	One year and three months	[16]
10	Female	67	Left adrenal gland	Cisplatin + epirubicin + ifosfamide	One year and seven months	[17]
11^†	Female	54	Uterus	CyVADIC-etoposide→IAP	Eleven months	[18]
12^†	Male	44	Spermatic cord	CyVADIC	Five months	[19]

CyVADIC: cyclophosphamide + vincristine + adriamycin + dacarbazine. IA: ifosfamide + adriamycin. CAP: cyclophosphamide + adriamycin + cisplatin. IAP: ifosfamide + adriamycin + cisplatin. MAID: ifosfamide + adriamycin. HEEp-DITC: hydroxycarbamide + epirubicin + etoposide + dacarbazine.
^†fatal case.